Table 2.
List of compounds on current DNDi pipeline.
| Compound | Target disease | Phase |
|---|---|---|
| Aminopyrazoles | VL/CL | Research Phase (Lead Optimization) |
| CGH VL Series 1 | VL | Research Phase (Lead Optimization) |
| DNDI-5421 and DNDI-5610 Oxaboroles | VL/CL | Research Phase (Lead Optimization) |
| Leish H2L | VL | Research Phase (Lead Optimization) |
| CpG D35 | PKDL/CL | Translation Phase (Pre-clinical) |
| DNDI-6148 Oxaborole | VL/CL | Translation Phase (Pre-clinical) |
| DNDI-0690 Nitromidazole | VL/CL | Translation Phase (Pre-clinical) |
| DNDI-5561 | VL | Translation Phase (Pre-clinical) |
PKDL: Post-kala-azar dermal leishmaniasis.
Data available at www.dndi.org. Aug, 2018.